Run­ning out of cash and cit­ed on fraud charges, Im­muno­Cel­lu­lar re­treats on PhI­II and cries for help

Things just keep get­ting worse and worse at Im­muno­Cel­lu­lar Ther­a­peu­tics $IMUC.

Three and a half years af­ter its lead can­cer vac­cine flopped in a Phase II glioblas­toma tri­al, some months af­ter its ac­coun­tant lev­eled a “go­ing con­cern” alert on the num­bers and just weeks af­ter one of its for­mer CEOs was cit­ed for a pho­ny stock pro­mo­tion scheme by the SEC, the floun­der­ing biotech has now been forced to call a halt to pa­tient as­sign­ments for its Phase III study af­ter run­ning short of cash to com­plete the job.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER